Clinical Trials Directory

Trials / Completed

CompletedNCT04928976

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

A Study to Evaluate the Ability of Speech- and Language-based Digital Biomarkers to Detect and Characterise Prodromal and Preclinical Alzheimer's Disease in a Clinical Setting

Status
Completed
Phase
Study type
Observational
Enrollment
67 (actual)
Sponsor
Novoic Limited · Industry
Sex
All
Age
50 Years – 85 Years
Healthy volunteers
Accepted

Summary

The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured by the AUC of the receiver operating characteristic (ROC) curve of the binary classifier distinguishing between amyloid positive (Arms 1 and 3) and amyloid negative (Arms 2 and 4) Arms. Secondary objectives include (1) evaluating whether similar algorithms can detect amyloid-specific cognitive impairment in the cognitively normal (CN) and MCI Arms respectively, as measured on binary classifier performance; (2) whether they can detect MCI, as measured on binary classifier performance (AUC, sensitivity, specificity, Cohen's kappa), and the agreement between the PACC5 composite and the corresponding regression model predicting it in all Arms pooled (Wilcoxon signed-rank test, CIA); (3) evaluating variables that can impact performance of such algorithms of covariates from the speaker (age, gender, education level) and environment (measures of acoustic quality).

Conditions

Timeline

Start date
2021-01-22
Primary completion
2021-07-30
Completion
2021-07-30
First posted
2021-06-16
Last updated
2021-09-05

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04928976. Inclusion in this directory is not an endorsement.